Product Description
GALE Antibody | 26-862 | ProSci
Host: Rabbit
Reactivity: Human
Homology: N/A
Immunogen: Antibody produced in rabbits immunized with a synthetic peptide corresponding a region of human GALE.
Research Area: Other
Tested Application: E, WB
Application: GALE antibody can be used for detection of GALE by ELISA at 1:312500. GALE antibody can be used for detection of GALE by western blot at 1 μg/mL, and HRP conjugated secondary antibody should be diluted 1:50, 000 - 100, 000.
Specificiy: N/A
Positive Control 1: Cat. No. XBL-10409 - Fetal Liver Tissue Lysate
Positive Control 2: N/A
Positive Control 3: N/A
Positive Control 4: N/A
Positive Control 5: N/A
Positive Control 6: N/A
Molecular Weight: 38 kDa
Validation: N/A
Isoform: N/A
Purification: Antibody is purified by peptide affinity chromatography method.
Clonality: Polyclonal
Clone: N/A
Isotype: N/A
Conjugate: Unconjugated
Physical State: Liquid
Buffer: Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose.
Concentration: batch dependent
Storage Condition: For short periods of storage (days) store at 4˚C. For longer periods of storage, store GALE antibody at -20˚C. As with any antibody avoid repeat freeze-thaw cycles.
Alternate Name: GALE, SDR1E1
User Note: Optimal dilutions for each application to be determined by the researcher.
BACKGROUND: GALE is an UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form) . This gene encodes UDP-galactose-4-epimerase which catalyzes two distinct but analogous reactions: the epimerization of UDP-glucose to UDP-galactose, and the epimerization of UDP-N-acetylglucosamine to UDP-N-acetylgalactosamine. The bifunctional nature of the enzyme has the important metabolic consequence that mutant cells (or individuals) are dependent not only on exogenous galactose, but also on exogenous N-acetylgalactosamine as a necessary precursor for the synthesis of glycoproteins and glycolipids. Mutations in this gene result in epimerase-deficiency galactosemia, also referred to as galactosemia type 3, a disease characterized by liver damage, early-onset cataracts, deafness and mental retardation, with symptoms ranging from mild ('peripheral' form) to severe ('generalized' form) . Multiple alternatively spliced transcripts encoding the same protein have been identified.